CHMP Issues Positive Opinion To Expand Jardiance®, Synjardy® And Glyxambi® Labels To Include Positive Effects On Cardiovascular And Renal Outcomes

Kurt HarringtonIndustry News, RegulatoryLeave a Comment

Boehringer Ingelheim Logo
Share This:

INGELHEIM, Germany & INDIANAPOLIS–(BUSINESS WIRE)–Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to update … Read More